Melanotan-2 is a synthetic analogue of the natural peptide hormone melanocortin (alpha-melanocyte-stimulating hormone (α-MSH)), which stimulates and enhances tanning (skin pigmentation) by the production of melanin pigment, which determines and makes tanning possible. The Italian Medical Agency (AIFA - Agenzia Italiana del Farmaco) approved Melanotan 2 as a therapeutic tool for Italian citizens that reduces painful sensitivity to sunlight.

The best way to protect your body against skin cancer is to initiate the activity of melanin in the cells, that facilitates the tanning process. The natural hormone α-MSH causes melanogenesis, a process by which skin pigmentation cells (melanocytes) produce skin pigment (melanin). Scientists have conducted research and made sure that the direct introduction of Melanotan 2 into the human body is an effective way to tan even without exposure to sunlight and, accordingly, the best way to prevent melanoma. The synthesized Melanotan 2 was most suitable for therapeutic use for this purpose. Now it is universally used to stimulate tanning, as well as a means of preventing melanoma and skin cancer.

One of these effects of sun exposure is also photoaging: the skin is dehydrated, unpleasant age spots and wrinkles appear on it. Cosmetics with UV filters are not always enough to provide the necessary protection. Using Melanotan 2 you can prepare your skin for the effects of solar radiation and protect against sunburn and allergies.

Melanotan 2 has the ability to stimulate sexual desire not only in men, but also in women, since it affects not the reproductive system, but the upper parts of the nervous system where libido occurs. Thus, the very inner attitude and feelings in sexual relations change, you immerse yourself more fully in them, your sexual needs increase, the sexual intercourse lasts longer, the quality of the erection increase, and you get more satisfaction.

A natural consequence of the mentioned above effects of Melanotan 2 is the ability to use it for weight loss and gaining nice wellness. On the one hand Melanotan 2 launches a number of processes in the body that make you more energetic and active, increase your self-esteem, and therefore your desire to look more attractive and perform the actions necessary for this. On the other hand, appetite is directly suppressed, the desire to consume large amounts of food and even thoughts about food lose their position in the list of the most demanded things for daily being.

The most effective way to use Melanotan 2 is in the form of injections. Other methods (tablets, sprays) do not provide expected effect due to the destruction of the active substance in the stomach and the instability of getting through the mucous membrane. Tanoliq® Pen Syringe allows you to accurately and safely inject Melanotan 2.

1 day 0.2 mg, 2 day 0.4 mg, 3 day 0.6 mg, 4 day 0.8 mg, 5 day 1 mg. Then 1 mg for 7-10 days until the desired shade of tan. Maintenance course - 1 mg once every 3 days.

1 day 0.2 mg, 2 day 0.4 mg, 3 day 0.6 mg. Then 0.6 mg for next 3 or 4 weeks.

Long-term use with lower dosages gives a deeper, even and lasting tan.

Each ml contains 6,7 mg melanotan 2, mannitol, sodium dihydrophosphate, sodium hydrophosphate, glycine, phenol (0,3%), water for injection. Carefully read the instructions for using the pen syringe in the Information section.

Desira® contains bremelanotide (pt-141). The effect of Desira® is based on its ability to bind to melanocortin receptors, which stimulates an improvement in the reaction of the higher parts of the nervous system to sexual incentives - appearance of a partner, ability to see a naked body and anticipation of sexual intercourse. Your sexual arousal becomes more sensitive, the level of emotional reactions increases, and involvement in sexual intercourse becomes urgent. Your sexual desire increases and you get more satisfaction.

The result of this, through positive feedback, is to increase your self-esteem and level of interest in your partner, which will help maintain the proper quality of sexual life in the future.

Desira® is equally effective for both men and women. The manifestations of libido in higher nervous activity are the same processes in both sexes. As for the genitals, women feel an improvement in the blood supply to the pelvic organs, which elevates the level of sensitivity during intercourse. Desira® also helps to cope with problems with erection in men if they are caused by a lack of interest in sex, but not by physiological characteristics, pathologies or damage to the vascular system of the penis.

There are 2 ways how to use Desira®.

1) Use 1.5 - 2 mg not later than 1 hour before sexual intercourse.
2) In the course of 1 mg daily for 3 weeks. This method is suitable if you want to form stable sexual relations and practices with a partner whom you consider permanent.

Each ml contains 6,7mg bremelanotide (pt-141) mannitol, monosodium phosphate, disodium phosphate, sodium chloride, hydrochloric acid, phenol (0,3%), water for injection.
Carefully read the instructions for using the pen syringe in the Information section.

Twincret®(Tirzepatide) is indicated as an adjunct to diet and phisical exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.

Tirzepatide lowers fasting and postprandial glucose concentration, decreases food intake, and reduces body weight in patients with type 2 diabetes mellitus. Tirzepatide enhances the first- and second-phase insulin secretion.

Insulin Sensitivity

Tirzepatide increases insulin sensitivity, as demonstrated in a hyperinsulinemic euglycemic clamp study after 28 weeks of treatment.

Glucagon Secretion

Tirzepatide reduces fasting and postprandial glucagon concentrations. Tirzepatide 15 mg reduced fasting glucagon concentration by 28% and glucagon AUC after a mixed meal by 43%, compared with no change for placebo after 28 weeks of treatment.

Gastric Emptying

Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time. Tirzepatide slows post-meal glucose absorption, reducing postprandial glucose. The impact of tirzepatide on gastric emptying was greatest after a single dose of 5 mg and diminished after subsequent doses.

During the SURMOUNT-1 study in 2022, which involved 2,539 participants and was the first global trial evaluating the efficacy and safety of tirzepatide in adults with obesity, or overweight with at least one comorbidity, who do not have diabetes., it was found that participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week study. The mean baseline body weight of participants was 231 lb. (105 kg). 63% of participants taking tirzepatide 15 mg achieved at least 20% body weight reductions. For the efficacy estimand, participants taking tirzepatide achieved average weight reductions of 16.0% (35 lb. or 16 kg on 5 mg per week), 21.4% (49 lb. or 22 kg on 10 mg per week) and 22.5% (52 lb. or 24 kg on 15 mg per week), compared to placebo (2.4%, 5 lb. or 2 kg). Additionally, 89% (5 mg) and 96% (10 mg and 15 mg) of people taking tirzepatide achieved at least 5% body weight reductions compared to 28% of those taking placebo.

Study conclusion:

Average body weight reductions for 72 weeks: 15.0% (5 mg per week ), 19.5% (10 mg per week), 20.9% (15 mg per week ), 3.1% (placebo) Percentage of participants achieving body weight reductions of ≥5%: 85% (5 mg per week), 89% (10 mg per week ), 91% (15 mg per week ), 35% (placebo) Percentage of participants achieving body weight reductions of ≥20%: 30% (5 mg per week), 50% (10 mg per week ), 57% (15 mg per week), 3.1% (placebo)

The overall safety and tolerability profile of tirzepatide was similar to other incretin-based therapies approved for the treatment of obesity. The most commonly reported adverse events were gastrointestinal-related and generally mild to moderate in severity, usually occurring during the dose escalation period and were mostly temporary. Treatment discontinuation rates due to adverse events were 4.3% (5 mg per week ), 7.1% (10 mg per week), 6.2% (15 mg per week) and 2.6% (placebo).

The newest study SURMOUNT-2 with a more rigorous design was completed in May 2023. The trial evaluated 938 adult participants with obesity or overweight and type 2 diabetes. Study participants had a mean baseline body weight of 222 lb. (100.7 kg). According to the study results:

Average body weight reductions for 72 week: 12.8% (or 13 kg on 10 mg per week), 14.7% ( or 15 kg on 15 mg per week), 3.2% (placebo) At week 40, changes in body weight were 8% (10 mg per week) and 9,2% (15 mg per week) Percentage of participants achieving body weight reductions of ≥5%: 79.2% (10 mg per week), 82.7% (15 mg per week ), 32.5% (placebo) Percentage of participants achieving body weight reductions of ≥15%: 39.7% (10 mg per week), 48.0% (15 mg per week ), 2.7% (placebo)

The overall safety profile of tirzepatide was similar to previously reported SURMOUNT and SURPASS trials and to incretin-based therapies approved for the treatment of obesity and overweight. The most commonly reported adverse events were gastrointestinal-related and generally mild to moderate in severity, usually occurring during the dose-escalation period and were mostly temporary. Treatment discontinuation rates due to adverse events were 3.8% (10 mg per week), 7.4% (15 mg per week) and 3.8% (placebo). The overall treatment discontinuation rates, together with reasons not related to the effect of the drug, were 9.3% (10 mg per week), 13.8% (15 mg per week) and 14.9% (placebo).

Thus, the therapeutic effectiveness of Tirzepatide, which is recommended to be prescribed to overweight patients with or without type 2 diabetes, in parallel with diet and exercise, has surpassed all existing antidiabetic drugs in terms of glycemic control and is currently the most effective means of weight loss body among antidiabetic drugs. Also can see that the effectiveness of Tirzepatide for overweight people not complicated by type 2 diabetes is much higher.

The recommended starting dosage of Twincret is 3 mg injected subcutaneously once weekly. The 3 mg dosage is for treatment initiation and is not intended for glycemic control.

After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.

After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.

If you need to inject more than 5 mg, you can give two injections in different areas no closer than 5 centimeters.

The maximum dosage of Twincret is 15 mg injected subcutaneously once weekly.

If a dose is missed, instruct patients to administer Twincret as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.

The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).

Administer Twincret once weekly, any time of day, with or without meals.

Inject Twincret subcutaneously in the abdomen, thigh, or upper arm.

Rotate injection sites with each dose.

When using Twincret with insulin, administer as separate injections and never mix. It is acceptable to inject Twincret and insulin in the same body region, but the injections should not be adjacent to each other.

Twincret is contraindicated in patients with:

A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Known serious hypersensitivity to tirzepatide or any of the excipients in Twincret. Possible hypersensitivity reactions. If there is a tendency to allergic reactions, it is recommended to conduct a subcutaneous test with 1 mg

Decreased appetite, nausea, constipation or diarrhea may occur. A significant decrease in the speed of digestion and a feeling of fullness in the stomach.